Showing results (51-60 of 174) with videos related to

Sort By:
Pageof 18
Immunotherapy|July 4, 2019
Safety and tolerability of subcutaneous immunoglobulin 20% in primary immunodeficiency diseases from two continentsDaniel Suez, Gergely Kriván, Stephen Jolles, et al.
The Journal of Antimicrobial Chemotherapy|May 30, 2023
High-titer convalescent plasma plus nirmatrelvir/ritonavir treatment for non-resolving COVID-19 in six immunocompromised patientsSammy Huygens, Arvind Gharbharan, Yasmina Serroukh, et al.
Frontiers in Ophthalmology|July 10, 2024
Long-term follow-up after treatment of tubercular uveitis: case series and review of the literatureIkhwanuliman Putera, Paul L A van Daele, Josianne C E M Ten Berge, et al.
Immunotherapy|June 18, 2024
Long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10%: a European post-authorization studyPauline M Ellerbroek, Leif G Hanitsch, Torsten Witte, et al.
The British Journal of Ophthalmology|February 12, 2011
Whole orbital tissue culture identifies imatinib mesylate and adalimumab as potential therapeutics for Graves' ophthalmopathyLeendert van Steensel, P Martin van Hagen, Dion Paridaens, et al.
Current Opinion in Allergy and Clinical Immunology|October 29, 2025
Pregnancy complications in women with an inborn error of immunity: a systematic reviewBengisu Yakut, Anna C R Knaapen, Xin Yu Cui, et al.
Allergy|April 30, 2026
Determinants of Immunoglobulin-G N-Glycan Patterns in the Aging General PopulationSamantha Leonard, Ralph Heijmans, Virgil A S H Dalm, et al.
Progress in Retinal and Eye Research|May 26, 2023
The immune response in tubercular uveitis and its implications for treatment: From anti-tubercular treatment to host-directed therapiesIkhwanuliman Putera, Benjamin Schrijver, Josianne C E M Ten Berge, et al.
The British Journal of Ophthalmology|February 15, 2015
Retinal pigment epithelial cells display specific transcriptional responses upon TNF-α stimulationNicoline M Korthagen, Kiki van Bilsen, Sigrid M A Swagemakers, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|June 26, 2018
The JAK1/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine releaseMaud A W Hermans, Benjamin Schrijver, Conny C P A van Holten-Neelen, et al.
Pageof 18